KR101962495B1 - C-kit 키나제 억제제로서의 화합물 및 조성물 - Google Patents
C-kit 키나제 억제제로서의 화합물 및 조성물 Download PDFInfo
- Publication number
- KR101962495B1 KR101962495B1 KR1020147008107A KR20147008107A KR101962495B1 KR 101962495 B1 KR101962495 B1 KR 101962495B1 KR 1020147008107 A KR1020147008107 A KR 1020147008107A KR 20147008107 A KR20147008107 A KR 20147008107A KR 101962495 B1 KR101962495 B1 KR 101962495B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyridine
- imidazo
- oxadiazol
- methylphenyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UCZGYKUXHGEQJT-UHFFFAOYSA-N Cc(c(NC(c1cnc2[n]1cccc2)=O)c1)ccc1/C(/N)=N/O Chemical compound Cc(c(NC(c1cnc2[n]1cccc2)=O)c1)ccc1/C(/N)=N/O UCZGYKUXHGEQJT-UHFFFAOYSA-N 0.000 description 2
- DHJJCDRDAUJMDB-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1c1nc(-c2ccc(C)c(NC(c3cnc4[n]3cccc4)=O)c2)n[o]1)=O Chemical compound CC(C)(C)OC(N(C1)CC1c1nc(-c2ccc(C)c(NC(c3cnc4[n]3cccc4)=O)c2)n[o]1)=O DHJJCDRDAUJMDB-UHFFFAOYSA-N 0.000 description 1
- WTBVRYPZNRJPSE-UHFFFAOYSA-N COCC(C(O)=O)N(CC1)CC1(F)F Chemical compound COCC(C(O)=O)N(CC1)CC1(F)F WTBVRYPZNRJPSE-UHFFFAOYSA-N 0.000 description 1
- NVBLRKGCQVZDMQ-UHFFFAOYSA-N COCC(C(OC)=O)Br Chemical compound COCC(C(OC)=O)Br NVBLRKGCQVZDMQ-UHFFFAOYSA-N 0.000 description 1
- JHPXWMLOFGOOCP-UHFFFAOYSA-N Cc(c(NC(c1cnc2[n]1cccc2)=O)c1)ccc1-c1n[o]c(CCl)n1 Chemical compound Cc(c(NC(c1cnc2[n]1cccc2)=O)c1)ccc1-c1n[o]c(CCl)n1 JHPXWMLOFGOOCP-UHFFFAOYSA-N 0.000 description 1
- DBLUMZONAFMQTH-UHFFFAOYSA-N Cc(c([N+]([O-])=O)c1)ccc1C(N1)=NOC1=O Chemical compound Cc(c([N+]([O-])=O)c1)ccc1C(N1)=NOC1=O DBLUMZONAFMQTH-UHFFFAOYSA-N 0.000 description 1
- ZARCPGLWMNKGEA-UHFFFAOYSA-N Cc(ccc(-c1n[o]c(C(C2)CN2C(OC)=O)n1)c1)c1N Chemical compound Cc(ccc(-c1n[o]c(C(C2)CN2C(OC)=O)n1)c1)c1N ZARCPGLWMNKGEA-UHFFFAOYSA-N 0.000 description 1
- FTWNIJSIMRDSPL-UHFFFAOYSA-N Cc(ccc(-c1n[o]c(C(C2)CN2C(OC)=O)n1)c1)c1NC(c1cnc2[n]1cc(CCC#N)cc2)=O Chemical compound Cc(ccc(-c1n[o]c(C(C2)CN2C(OC)=O)n1)c1)c1NC(c1cnc2[n]1cc(CCC#N)cc2)=O FTWNIJSIMRDSPL-UHFFFAOYSA-N 0.000 description 1
- RGZVFNJQTQXPPZ-UHFFFAOYSA-N Cc(ccc(-c1n[o]c(C2CNC2)n1)c1)c1NC(c1cnc2[n]1cccc2)=O Chemical compound Cc(ccc(-c1n[o]c(C2CNC2)n1)c1)c1NC(c1cnc2[n]1cccc2)=O RGZVFNJQTQXPPZ-UHFFFAOYSA-N 0.000 description 1
- JCEHLKKIUWHFKA-UHFFFAOYSA-N Cc(ccc(-c1n[o]c(Cl)n1)c1)c1[N+]([O-])=O Chemical compound Cc(ccc(-c1n[o]c(Cl)n1)c1)c1[N+]([O-])=O JCEHLKKIUWHFKA-UHFFFAOYSA-N 0.000 description 1
- KCLVHCQKQSOAJC-UHFFFAOYSA-N Cc(ccc(-c1n[o]c(N2CCC2)n1)c1)c1N Chemical compound Cc(ccc(-c1n[o]c(N2CCC2)n1)c1)c1N KCLVHCQKQSOAJC-UHFFFAOYSA-N 0.000 description 1
- GZHQQAJNYCMUEU-UHFFFAOYSA-N Cc(ccc(-c1n[o]c(N2CCC2)n1)c1)c1[N+]([O-])=O Chemical compound Cc(ccc(-c1n[o]c(N2CCC2)n1)c1)c1[N+]([O-])=O GZHQQAJNYCMUEU-UHFFFAOYSA-N 0.000 description 1
- LYAOQDSZXTXCHL-UHFFFAOYSA-N Cc(ccc(/C(/N)=N/O)c1)c1[N+]([O-])=O Chemical compound Cc(ccc(/C(/N)=N/O)c1)c1[N+]([O-])=O LYAOQDSZXTXCHL-UHFFFAOYSA-N 0.000 description 1
- MUHWSSBYQZREGO-UHFFFAOYSA-N N#CCCc(cc1)c[n]2c1ncc2C(O)=O Chemical compound N#CCCc(cc1)c[n]2c1ncc2C(O)=O MUHWSSBYQZREGO-UHFFFAOYSA-N 0.000 description 1
- NPYFIPGVKXPGFP-UHFFFAOYSA-N N/C(/c(cc1)cc(NC(c2cnc3[n]2cccc3)=O)c1F)=N\O Chemical compound N/C(/c(cc1)cc(NC(c2cnc3[n]2cccc3)=O)c1F)=N\O NPYFIPGVKXPGFP-UHFFFAOYSA-N 0.000 description 1
- PNVPNXKRAUBJGW-UHFFFAOYSA-N O=C(CCl)OC(CCl)=O Chemical compound O=C(CCl)OC(CCl)=O PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530038P | 2011-09-01 | 2011-09-01 | |
| US61/530,038 | 2011-09-01 | ||
| PCT/US2012/052802 WO2013033167A1 (en) | 2011-09-01 | 2012-08-29 | Compounds and compositions as c-kit kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140075692A KR20140075692A (ko) | 2014-06-19 |
| KR101962495B1 true KR101962495B1 (ko) | 2019-03-26 |
Family
ID=46829904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147008107A Active KR101962495B1 (ko) | 2011-09-01 | 2012-08-29 | C-kit 키나제 억제제로서의 화합물 및 조성물 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8569283B2 (https=) |
| EP (1) | EP2751104B1 (https=) |
| JP (1) | JP6134319B2 (https=) |
| KR (1) | KR101962495B1 (https=) |
| CN (1) | CN103797011B (https=) |
| AP (1) | AP2014007493A0 (https=) |
| AR (1) | AR087753A1 (https=) |
| AU (1) | AU2012302042B2 (https=) |
| BR (1) | BR112014004560A2 (https=) |
| CA (1) | CA2845169C (https=) |
| CL (1) | CL2014000492A1 (https=) |
| CO (1) | CO6900141A2 (https=) |
| CR (1) | CR20140107A (https=) |
| CU (1) | CU20140024A7 (https=) |
| EA (1) | EA026152B1 (https=) |
| ES (1) | ES2761332T3 (https=) |
| GT (1) | GT201400034A (https=) |
| IL (1) | IL231227A0 (https=) |
| MA (1) | MA35460B1 (https=) |
| MX (1) | MX339937B (https=) |
| PE (1) | PE20140909A1 (https=) |
| PH (1) | PH12014500372A1 (https=) |
| PL (1) | PL2751104T3 (https=) |
| PT (1) | PT2751104T (https=) |
| SG (1) | SG2014014369A (https=) |
| TN (1) | TN2014000068A1 (https=) |
| TW (1) | TW201313717A (https=) |
| UY (1) | UY34301A (https=) |
| WO (1) | WO2013033167A1 (https=) |
| ZA (1) | ZA201401175B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103797011B (zh) | 2011-09-01 | 2016-03-30 | 诺华股份有限公司 | 作为c-Kit激酶抑制剂的化合物和组合物 |
| US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| EP3007689B1 (en) | 2013-01-10 | 2018-03-07 | Pulmokine, Inc. | Non-selective kinase inhibitors |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US9925184B2 (en) | 2013-10-11 | 2018-03-27 | Pulmokine, Inc. | Spray-dry formulations |
| US20150288928A1 (en) * | 2014-04-08 | 2015-10-08 | Sony Corporation | Security camera system use of object location tracking data |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| UA125171C2 (uk) | 2015-07-02 | 2022-01-26 | Янссен Саєнсиз Айрленд Юсі | Антибактеріальні сполуки |
| US10474987B2 (en) * | 2015-08-05 | 2019-11-12 | Whirlpool Corporation | Object recognition system for an appliance and method for managing household inventory of consumables |
| US20190256509A1 (en) * | 2016-06-08 | 2019-08-22 | Chrysalis, Inc. | Histone demethylase inhibitors |
| JP2019518046A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| US20200308169A1 (en) | 2016-06-16 | 2020-10-01 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| RU2763525C2 (ru) | 2016-10-27 | 2021-12-30 | Пульмокин, Инк. | Комбинированная терапия для лечения легочной гипертензии |
| US20180162291A1 (en) * | 2016-12-12 | 2018-06-14 | Wipro Limited | System and method of dynamically adjusting field of view of an image capturing device |
| KR20190121315A (ko) | 2017-03-01 | 2019-10-25 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 병용 요법 |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| KR102625224B1 (ko) * | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| MA55976A (fr) * | 2019-05-13 | 2022-03-23 | Novartis Ag | Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| WO2021035788A1 (zh) | 2019-08-29 | 2021-03-04 | 中国科学院合肥物质科学研究院 | 吡唑衍生物及其用途 |
| US20220340564A1 (en) | 2019-09-13 | 2022-10-27 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| TWI893032B (zh) | 2019-12-13 | 2025-08-11 | 日商日本新藥股份有限公司 | 作為pdgf受體激酶抑制劑之化合物及組合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP2023534963A (ja) | 2020-07-15 | 2023-08-15 | サード ハーモニック バイオ， インコーポレイテッド | 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態 |
| US11744823B2 (en) | 2020-11-19 | 2023-09-05 | Third Harmonic Bio, Inc. | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same |
| MX2023010947A (es) | 2021-03-16 | 2023-11-29 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| MX2023010941A (es) | 2021-03-17 | 2023-11-28 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| CA3211592A1 (en) | 2021-03-17 | 2022-09-22 | Jerome Emile Georges Guillemont | Antibacterial compounds |
| EP4423097A1 (en) | 2021-10-28 | 2024-09-04 | Janssen Sciences Ireland Unlimited Company | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| JP2025540958A (ja) * | 2022-11-30 | 2025-12-17 | ブループリント メディシンズ コーポレイション | 蕁麻疹の治療のための野生型ｃ－ｋｉｔキナーゼ阻害剤としてのＮ－フェニル－ピラゾロ［１，５－Ａ］ピリジン－３－カルボキサミド誘導体 |
| WO2024123966A1 (en) * | 2022-12-07 | 2024-06-13 | Third Harmonic Bio, Inc. | Compounds and compositions as c-kit kinase inhibitors |
| AU2023390239A1 (en) * | 2022-12-07 | 2025-07-24 | Third Harmonic Bio, Inc. | Compounds and compositions as c-kit kinase inhibitors |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025072330A1 (en) * | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| WO2025256552A1 (zh) * | 2024-06-11 | 2025-12-18 | 上海翰森生物医药科技有限公司 | 吡唑类衍生物抑制剂、其制备方法和应用 |
| WO2025256609A1 (en) * | 2024-06-13 | 2025-12-18 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
| WO2025259929A1 (en) * | 2024-06-13 | 2025-12-18 | Third Harmonic Bio, Inc. | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072862A1 (en) | 2005-08-15 | 2007-03-29 | Dimauro Erin F | Bis-aryl amide compounds and methods of use |
| WO2008058037A1 (en) | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003251561A1 (en) | 2002-06-20 | 2004-01-06 | Beacon Looms, Inc. | Knitted electrical conductor fabric |
| UA94570C2 (en) | 2004-09-09 | 2011-05-25 | Натко Фарма Лимитед | Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
| WO2006071940A2 (en) | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
| AU2011329233A1 (en) * | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| US20130023751A1 (en) | 2011-07-18 | 2013-01-24 | Samuel Victor Lichtenstein | Water retention monitoring |
| US20150051206A1 (en) | 2011-09-01 | 2015-02-19 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| CN103797011B (zh) | 2011-09-01 | 2016-03-30 | 诺华股份有限公司 | 作为c-Kit激酶抑制剂的化合物和组合物 |
| KR20140105433A (ko) | 2011-09-01 | 2014-09-01 | 아이알엠 엘엘씨 | Pdgfr 키나제 억제제로서의 화합물 및 조성물 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
-
2012
- 2012-08-29 CN CN201280042743.4A patent/CN103797011B/zh active Active
- 2012-08-29 EP EP12756885.5A patent/EP2751104B1/en active Active
- 2012-08-29 CA CA2845169A patent/CA2845169C/en active Active
- 2012-08-29 JP JP2014528537A patent/JP6134319B2/ja active Active
- 2012-08-29 PE PE2014000295A patent/PE20140909A1/es not_active Application Discontinuation
- 2012-08-29 MX MX2014002484A patent/MX339937B/es active IP Right Grant
- 2012-08-29 PL PL12756885T patent/PL2751104T3/pl unknown
- 2012-08-29 UY UY34301A patent/UY34301A/es not_active Application Discontinuation
- 2012-08-29 PH PH1/2014/500372A patent/PH12014500372A1/en unknown
- 2012-08-29 WO PCT/US2012/052802 patent/WO2013033167A1/en not_active Ceased
- 2012-08-29 AP AP2014007493A patent/AP2014007493A0/xx unknown
- 2012-08-29 KR KR1020147008107A patent/KR101962495B1/ko active Active
- 2012-08-29 EA EA201490545A patent/EA026152B1/ru not_active IP Right Cessation
- 2012-08-29 BR BR112014004560A patent/BR112014004560A2/pt not_active Application Discontinuation
- 2012-08-29 SG SG2014014369A patent/SG2014014369A/en unknown
- 2012-08-29 US US13/598,213 patent/US8569283B2/en active Active
- 2012-08-29 AU AU2012302042A patent/AU2012302042B2/en not_active Ceased
- 2012-08-29 ES ES12756885T patent/ES2761332T3/es active Active
- 2012-08-29 PT PT127568855T patent/PT2751104T/pt unknown
- 2012-08-31 TW TW101131942A patent/TW201313717A/zh unknown
- 2012-08-31 AR ARP120103223 patent/AR087753A1/es unknown
-
2013
- 2013-09-19 US US14/031,792 patent/US8754071B2/en active Active
-
2014
- 2014-02-17 ZA ZA2014/01175A patent/ZA201401175B/en unknown
- 2014-02-17 TN TNP2014000068A patent/TN2014000068A1/en unknown
- 2014-02-27 CU CU20140024A patent/CU20140024A7/es unknown
- 2014-02-27 GT GT201400034A patent/GT201400034A/es unknown
- 2014-02-27 CL CL2014000492A patent/CL2014000492A1/es unknown
- 2014-02-27 IL IL231227A patent/IL231227A0/en unknown
- 2014-02-28 CO CO14043417A patent/CO6900141A2/es unknown
- 2014-02-28 CR CR20140107A patent/CR20140107A/es unknown
- 2014-03-28 MA MA36864A patent/MA35460B1/fr unknown
- 2014-04-22 US US14/258,963 patent/US9023839B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072862A1 (en) | 2005-08-15 | 2007-03-29 | Dimauro Erin F | Bis-aryl amide compounds and methods of use |
| WO2008058037A1 (en) | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101962495B1 (ko) | C-kit 키나제 억제제로서의 화합물 및 조성물 | |
| KR101959590B1 (ko) | c-KIT 키나제 억제제로서의 화합물 및 조성물 | |
| KR20140071384A (ko) | C-kit 키나제 억제제로서의 화합물 및 조성물 | |
| KR20140071383A (ko) | C-kit 키나제 억제제로서의 화합물 및 조성물 | |
| KR20140105433A (ko) | Pdgfr 키나제 억제제로서의 화합물 및 조성물 | |
| HK1193821B (en) | Compounds and compositions as c-kit kinase inhibitors | |
| HK1193821A (en) | Compounds and compositions as c-kit kinase inhibitors | |
| HK1193820B (en) | Compounds and compositions as c-kit kinase inhibitors | |
| HK1193820A (en) | Compounds and compositions as c-kit kinase inhibitors | |
| NZ621092B2 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140327 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20160502 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20160503 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170828 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20181001 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20190304 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20190320 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20190320 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20220307 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220307 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230307 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240306 Start annual number: 6 End annual number: 6 |